Form 4: Privia Health CFO Mountcastle Sells Shares

Privia Health Group, Inc.'s EVP & Chief Financial Officer, David Mountcastle, executed a planned sale of common stock following option exercises.

Summary

• David Mountcastle, EVP & Chief Financial Officer of Privia Health Group, Inc. (PRVA), reported transactions involving the company's common stock.
• On February 26, 2026, Mountcastle acquired 5,361 shares of common stock by exercising stock options at an exercise price of $2.00 per share.
• Immediately following the option exercise on February 26, 2026, he sold 5,361 shares of common stock at a weighted average price of $25.00 per share, ranging from $25.00 to $25.02.
• On February 27, 2026, Mountcastle acquired an additional 7,697 shares of common stock by exercising stock options at an exercise price of $2.00 per share.
• Following this second option exercise on February 27, 2026, he sold 7,697 shares of common stock at a weighted average price of $25.05 per share, ranging from $25.00 to $25.19.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
• After these transactions, Mountcastle directly beneficially owns 172,909 shares of common stock and indirectly owns 8,695 shares through his spouse.
• All stock options exercised were fully vested and exercisable.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, reflecting the exercise of vested options and subsequent sale for personal liquidity, rather than a signal of company performance.

Positives

• The executive exercised stock options at a low price ($2.00) and sold the shares at a significantly higher market price (weighted average of $25.00 and $25.05), indicating a substantial profit from his compensation package.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing personal holdings rather than a reaction to immediate company news.

Negatives

• The sale of shares by a key executive, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although this is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are a common occurrence in publicly traded companies. These plans allow insiders to pre-arrange sales of company stock to avoid accusations of trading on material non-public information, often for personal financial planning or diversification. Such routine transactions typically do not signal a change in the company's fundamental business operations or strategic direction within the healthcare services industry.

Comparison to Industry Standards

• Insider selling under a 10b5-1 plan is a standard practice for executives managing their equity compensation and personal finances, aligning with corporate governance best practices to mitigate insider trading concerns.
• The significant difference between the exercise price ($2.00) and the sale price (around $25.00) is typical for long-term equity incentive plans where stock options are granted at a low strike price and become valuable as the company's stock appreciates, similar to compensation structures seen at other growth-oriented healthcare technology and services companies.

Related Party Transactions

• The reporting person indirectly owns 8,695 shares of common stock through his spouse, which is a disclosed related party holding.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be viewed neutrally to slightly negatively, though the 10b5-1 plan mitigates concerns about opportunistic selling. The volume of shares sold represents a small fraction of the company's total outstanding shares, so the direct market impact is likely minimal.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 details a pre-planned exercise of stock options and subsequent sale of shares by a key executive. Such transactions are common for liquidity and compensation purposes and do not inherently signal a change in the company's fundamental outlook. Investors should consider broader company performance and market conditions rather than this routine insider activity alone.

Keywords

Privia Health Group, PRVA, David Mountcastle, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CFO, Beneficial Ownership